Expands focus on gram-negative bacteria by adding Potentiator program to pipeline of novel antibiotic compounds.
CAMBRIDGE, Mass.– June 8, 2015 – Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, announced that the company secured $30M million in a Series A financing. Lundbeckfond Ventures led the round as a new investor with participation from additional new investors Merck Research Ventures and The Kraft Group. All existing investors participated including Atlas Venture, SR One, and Partners Innovation Fund. The company also expanded its pipeline of novel anti-infectives through the addition of a Potentiator program targeting Gram-negative infections. Spero plans to use the proceeds from this financing to advance the potentiator franchise into the clinic by 2016, progress its anti-virulence program in partnership with Roche through the submission of an Investigational New Drug (IND) application, and develop additional programs in its pipeline focused on unmet medical needs in bacterial infections.
Lund, Sweden, (PRNEWSWIRE) May 27, 2015 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced results from a pivotal pre-clinical study of CERAMENT™|G as presented at the 2015 Orthopedic Research Society (ORS) Annual Meeting. The study assessed the efficacy and safety of CERAMENT™|G, the first injectable gentamicin eluting bone substitute, in the completeness of bone healing after surgery and in the eradication of chronic infection. Study results demonstrated that CERAMENT™|G increased new bone growth and decreased the rate of infection as compared to treatment without a bone filler and treatment with CERAMENT™|BONE VOIDE FILLER without gentamicin.
|Forrige 1 2 3 4 5 6 7 8 9 10 Næste 10 Næste|